Literature DB >> 16889572

Prevention programmes of progressive renal disease in developing nations.

Igor Codreanu1, Norberto Perico, Sanjib K Sharma, Arrigo Schieppati, Giuseppe Remuzzi.   

Abstract

Development of strategies for the early detection and prevention of non-communicable diseases, including kidney disease, is the only realistic strategy to avert an imminent global health and economic crisis and enhance equity in health care worldwide. In this article, we briefly examine the burden of non-communicable diseases, including diabetes, hypertension, cardiovascular disease and how chronic kidney disease (CKD) represents a key integrated element in the setting, even in developing countries. A possible explanation of the increasing number of people who have or are at risk to develop CKD in poor countries is also given. A survey of major screening and intervention programmes performed or ongoing globally is then presented, highlighting differences and hurdles of projects planned in developed or developing nations as well as in unprivileged communities in developed countries. Finally, some recommendations on future steps to implement prevention programmes in emerging worlds are provided.

Entities:  

Mesh:

Year:  2006        PMID: 16889572     DOI: 10.1111/j.1440-1797.2006.00587.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  16 in total

1.  The impact of aluminum, fluoride, and aluminum-fluoride complexes in drinking water on chronic kidney disease.

Authors:  Hewa M S Wasana; Gamage D R K Perera; Panduka S De Gunawardena; Jayasundera Bandara
Journal:  Environ Sci Pollut Res Int       Date:  2015-03-20       Impact factor: 4.223

2.  Drinking water quality and chronic kidney disease of unknown etiology (CKDu): synergic effects of fluoride, cadmium and hardness of water.

Authors:  Hewa M S Wasana; Dharshani Aluthpatabendi; W M T D Kularatne; Pushpa Wijekoon; Rohan Weerasooriya; Jayasundera Bandara
Journal:  Environ Geochem Health       Date:  2015-04-10       Impact factor: 4.609

3.  Evaluation of the impact of pharmaceutical care service on hospitalized patients with chronic kidney disease in Jordan.

Authors:  Salah M AbuRuz; Yazan Alrashdan; Anan Jarab; Deema Jaber; Izzat A Alawwa
Journal:  Int J Clin Pharm       Date:  2013-07-25

4.  Chronic kidney diseases of uncertain etiology (CKDue) in Sri Lanka: geographic distribution and environmental implications.

Authors:  Rohana Chandrajith; Shanika Nanayakkara; Kozuyoshi Itai; T N C Aturaliya; C B Dissanayake; Thilak Abeysekera; Kouji Harada; Takao Watanabe; Akio Koizumi
Journal:  Environ Geochem Health       Date:  2010-09-18       Impact factor: 4.609

5.  Population-based screening for CKD.

Authors:  Neil R Powe; L Ebony Boulware
Journal:  Am J Kidney Dis       Date:  2009-03       Impact factor: 8.860

6.  End-stage kidney disease and rationing of kidney replacement therapy in the free state province, South Africa: a retrospective study.

Authors:  Thabang T Molaoa; Feziwe B Bisiwe; Kwazi Cz Ndlovu
Journal:  BMC Nephrol       Date:  2021-05-11       Impact factor: 2.388

7.  Incidence, Development, and Prognosis of Diabetic Kidney Disease in China: Design and Methods.

Authors:  Yao-Zheng Yang; Jin-Wei Wang; Fang Wang; Yun-Tao Wu; Hai-Yan Zhao; Min Chen; Lu-Xia Zhang; Shou-Ling Wu; Ming-Hui Zha
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

8.  Effects of exercise on kidney function among non-diabetic patients with hypertension and renal disease: randomized controlled trial.

Authors:  Franklin C Barcellos; Iná S Santos; Grégore Iven Mielke; Fabrício B del Vecchio; Pedro C Hallal
Journal:  BMC Nephrol       Date:  2012-08-28       Impact factor: 2.388

9.  Sickle cell trait is not associated with chronic kidney disease in adult Congolese patients: a clinic-based, cross-sectional study.

Authors:  K Mukendi; F B Lepira; J R Makulo; K E Sumaili; P K Kayembe; M N Nseka
Journal:  Cardiovasc J Afr       Date:  2015 May-Jun       Impact factor: 1.167

10.  Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial.

Authors:  Jia Kou; Jie Wu; Hong-tao Yang; Ya-ni He; Jing-ai Fang; Yue-yi Deng; Yuan-sheng Xie; Li-fang Nie; Hong-li Lin; Guang-yan Cai; Xiang-mei Chen
Journal:  Trials       Date:  2014-12-05       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.